clinical trial · NCT05216224
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Hidradenitis SuppurativaATI-450Placebo oral tablet
brief summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
started
Dec 29, 2021
primary completion
Dec 23, 2022
completion
Jan 24, 2023
last updated
Jan 7, 2026
official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol